Immutep Limited (IMMP)
NASDAQ: IMMP · IEX Real-Time Price · USD
2.650
+0.050 (1.92%)
At close: Apr 26, 2024, 4:00 PM
2.570
-0.080 (-3.02%)
After-hours: Apr 26, 2024, 6:48 PM EDT
Immutep Revenue
Immutep had revenue of $4.58M in the twelve months ending December 31, 2023. In the fiscal year ending June 30, 2023, Immutep had annual revenue of $3.59M, a decrease of -23.58%.
Revenue (ttm)
$4.58M
Revenue Growth
-23.58%
P/S Ratio
76.20
Revenue / Employee
$111,628
Employees
41
Market Cap
348.77M USD
Revenue Chart
* The company reports in AUD currency but revenue data is shown in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Jun 30, 2023 | 3.59M | -1.11M | -23.58% |
Jun 30, 2022 | 4.69M | 1.71M | 57.30% |
Jun 30, 2021 | 2.98M | -8.40M | -73.78% |
Jun 30, 2020 | 11.38M | 6.11M | 115.75% |
Jun 30, 2019 | 5.27M | -172.67K | -3.17% |
Jun 30, 2018 | 5.45M | 2.20M | 67.77% |
Jun 30, 2017 | 3.25M | 1.74M | 114.92% |
Jun 30, 2016 | 1.51M | -102.31K | -6.34% |
Jun 30, 2015 | 1.61M | -1.35M | -45.47% |
Jun 30, 2014 | 2.96M | -704.67K | -19.24% |
Jun 30, 2013 | 3.66M | -632.41K | -14.72% |
Jun 30, 2012 | 4.30M | 3.15M | 275.71% |
Jun 30, 2011 | 1.14M | 699.68K | 157.75% |
Jun 30, 2010 | 443.55K | 420.00K | 1,783.04% |
Jun 30, 2009 | 23.56K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Amarin Corporation | 306.91M |
Health Catalyst | 295.94M |
Revance Therapeutics | 234.04M |
Zynex | 184.32M |
ADC Therapeutics | 69.56M |
Mersana Therapeutics | 36.86M |
Precigen | 6.23M |
Sera Prognostics | 306.00K |
IMMP News
- 3 days ago - Immutep Announces Positive Preliminary Topline Results from TACTI-003 Cohort B - GlobeNewsWire
- 9 days ago - Immutep Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP761 - GlobeNewsWire
- 10 days ago - Immutep Receives Positive Feedback from the Spanish Medicines Agency for Upcoming TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer - GlobeNewsWire
- 7 weeks ago - Immutep Announces First Clinical Data from 90mg Dosing of Efti - GlobeNewsWire
- 3 months ago - Immutep Quarterly Activities Report Q2 FY24 - GlobeNewsWire
- 4 months ago - First Patient Dosed in Trial Evaluating Efti and the Anti-PD-L1 Therapy BAVENCIO® in Metastatic Urothelial Cancer - GlobeNewsWire
- 4 months ago - Immutep Receives Constructive Regulatory Feedback on TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer - GlobeNewsWire
- 5 months ago - Immutep Receives A$2.6 million R&D Tax Incentive from French Government - GlobeNewsWire